Psoriasis Sprays: Niche Opportunities?
Expanding treatment options for psoriasis highlight how some firms are developing innovative "lower risk" assets that use established active ingredients but could provide benefits to specific patient segments.
You may also be interested in...
Dr Reddy's Laboratories (DRL) appears to be building on plans for its differentiated dermatology and neurology formulations in the US after gains on the approvals front.
Dr Reddy's Laboratories will take XenoPort's clinical-stage oral psoriasis NCE, XP23829, further in the US, infusing new hope in the prodrug of monomethyl fumarate (MMF) that has seen some safety issues in earlier studies and faces significant competition in the space.